Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depigmented polymerized Parietaria judaica pollen extract
- Development stage
- Phase 3
- Lead developer
- Leti Pharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Depigmented polymerized Parietaria judaica pollen extract is a chemically modified allergen extract (allergoid) developed and manufactured by Laboratorios LETI S.L. (LETI Pharma). It is produced by depigmenting Parietaria judaica pollen extract via controlled acid treatment to remove adsorbed pigments, followed by polymerization with glutaraldehyde. This chemical modification reduces the allergen's IgE-binding capacity (allergenicity) while preserving its immunogenicity, allowing for safer and more rapid updosing during immunotherapy. The extract is adsorbed onto aluminum hydroxide and administered via subcutaneous injection (SCIT). It is marketed under the brand name Depigoid® and is indicated for the treatment of allergic rhinoconjunctivitis and allergic asthma caused by hypersensitivity to Parietaria judaica pollen, a major source of seasonal respiratory allergies in the Mediterranean region.
- Brand names
- DepigoidDepigoid Parietaria judaica
- Other names
- Depigoid Parietaria judaica 1000 DPP/mldepigmented and glutaraldehyde-polymerised allergen extract of Parietaria judaica adsorbed onto aluminium hydroxide
02
Targets
Parietaria judaica allergen-specific immunoglobulin E
Beyond the preview
Go deeper on depigmented polymerized Parietaria judaica pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depigmented polymerized Parietaria judaica pollen extract.